AryaMShergilIFernandoH, et al. Viva practice for the FRCS (Urol) and postgraduate urology examinations. 2nd ed. London: CRC Publishing, 2018.
2.
ThompsonRHKurtaJMKaagM, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol2009;181: 2033–2036.
3.
ThompsonRHHillJRBabayevY, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol2009;182: 41–45.
4.
JewettMAMattarKBasiukJ, et al. Active surveillance of small renal masses: Progression patterns of early stage kidney cancer. Eur Urol2011;60: 39–44.
5.
Van PoppelHDa PozzoLAlbrechtW, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol2011;59: 543–552.
6.
RiveroJDe La Cerda3rdJWangH, et al. Partial nephrectomy versus thermal ablation for clinical stage T1 renal masses: Systematic review and meta-analysis of more than 3,900 patients. J Vasc Interv Radiol2018;29: 18–29.
7.
LaneBRTiongHYCampbellSC, et al. Management of the adrenal gland during partial nephrectomy. J Urol2009;181: 2430–2436.
8.
BlomJHvan PoppelHMaréchalJM, et al. EORTC Genitourinary Tract Cancer Group. Radical nephrectomy with and without lymph-node dissection: Final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol2009;55: 28–34.
9.
LeibovichBCBluteMLChevilleJC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer2003;97: 1663–1671.
10.
LeibovichBCLohseCMCrispenPL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol2010;183: 1309–1315.
11.
HengDXieWReganM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: Results from a large, multicenter study. J Clin Oncol2009;27: 5794–5799.
12.
FlaniganRCMickischGSylvesterR, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol2004;171: 1071–1076.
13.
MéjeanARavaudAThezenasS, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med2018;379: 417–427.
14.
BexAMuldersPJewettM, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized clinical trial. JAMA Oncol2019;5: 164–170.
